JPH0825895B2 - How to use Funori - Google Patents
How to use FunoriInfo
- Publication number
- JPH0825895B2 JPH0825895B2 JP5050210A JP5021093A JPH0825895B2 JP H0825895 B2 JPH0825895 B2 JP H0825895B2 JP 5050210 A JP5050210 A JP 5050210A JP 5021093 A JP5021093 A JP 5021093A JP H0825895 B2 JPH0825895 B2 JP H0825895B2
- Authority
- JP
- Japan
- Prior art keywords
- funori
- hiv
- cells
- drink
- infection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000000034 method Methods 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 2
- 238000002844 melting Methods 0.000 claims 2
- 230000008018 melting Effects 0.000 claims 2
- 239000000126 substance Substances 0.000 description 6
- 208000030507 AIDS Diseases 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 208000018501 Lymphatic disease Diseases 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 208000027932 Collagen disease Diseases 0.000 description 3
- 206010043376 Tetanus Diseases 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 102100034343 Integrase Human genes 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 235000010575 Pueraria lobata Nutrition 0.000 description 1
- 241000219781 Pueraria montana var. lobata Species 0.000 description 1
- 241000206572 Rhodophyta Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Description
【０００１】[0001]
【産業上の利用分野】本発明は紅藻類の一種として知ら
れているフノリの新規な使用方法に関する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a novel method of using funori known as a kind of red algae.
【０００２】一般的にフノリは壁土に混入されたり、丸
薬の成形等に使用され、いわゆるつなぎ材として利用さ
れ、あるいは古くは和服の洗浄等にも利用されていたに
すぎないものである。しかしながら、出願人は永年に亘
る研究と経験より、このフノリに特異な坑ウイルスの有
効性があることを知った。Generally, funori is mixed with wall soil, used for molding pills, used as a so-called tie material, or used to wash kimono in old times. However, the applicant has learned from many years of research and experience that the fungus-specific antivirus is effective.
【０００３】近時、社会的な大問題となっているエイズ
といわれる後天性免疫不全症候群は患者を死に至らしめ
る重大な病気であり、この原因はレトロウイルスである
ＨＩＶ（Ｈｕｍａｎ Ｉｎｍｕｎｏｄｅｆｉｃｉｅｎｅ
ｙ Ｖｉｒｕｓ）がヒトのＴ4リンパ系細胞に付着する
ことで感染がはじまり、他のリンパ系細胞に次々と感染
して免疫系を破壊することにあるのは既に知られてい
る。Acquired immunodeficiency syndrome, called AIDS, which has become a major social problem these days, is a serious illness that kills patients. The cause is a retrovirus, HIV (Human Immunodeficiene).
It has been already known that y virus) attaches to human T 4 lymphoid cells to initiate infection, which in turn infects other lymphoid cells to destroy the immune system.
【０００４】即ち、ＨＩＶがヒトのリンパ系細胞への付
着を阻害し、あるいはそのＨＩＶの増殖に必須の物質の
活性を阻害すればエイズの感染を抑制できることが理解
され、同時にエイズの他にも破傷風、膠原病といったリ
ンパ系疾病の治癒にも有効であることが解る。That is, it is understood that HIV can suppress the infection of AIDS by inhibiting the adhesion to human lymphoid cells or inhibiting the activity of the substance essential for the proliferation of HIV, and at the same time, in addition to AIDS. It can be seen that it is also effective in healing lymphatic diseases such as tetanus and collagen disease.
【０００５】[0005]
【発明の目的】そこで、本発明は上記した前提に基づ
き、リンパ系疾病の感染防止、ＢＲＭ（Ｂｉｏｌｏｇｉ
ｃａｌ Ｒｅｓｐｏｎｓｅ Ｍｏｄｉｆｉｅｒ）作用を
得るため、新規なフノリの使用方法を提供することにあ
る。SUMMARY OF THE INVENTION Therefore, the present invention is based on the above-mentioned premise, and prevents infection of lymphatic diseases and BRM (Biologic).
It is to provide a novel method of using funori in order to obtain a cal response modifier action.
【０００６】[0006]
【課題を解決するための手段】この目的を達成するため
に、本発明に係るフノリの使用方法はフノリを融解して
流体液状とし、飲用物とすることとフノリを融解して保
形液状とし、飲用物もしくは食用物とすることを特徴と
している。In order to achieve this object, the method of using Funori according to the present invention is to melt Funori into a fluid liquid, to make it a drink, and to melt Funori into a shape-retaining liquid. The feature is that it is a drink or an edible product.
【０００７】[0007]
【作用】上記した構成方法を採ることにより、フノリの
有効成分が格別な不純物や化学的な添加物なくダイレク
トに体内へ入り、吸収されることでリンパ系細胞に短時
間で作用していき、ＨＩＶをはじめとするウイルス感染
やその進行を抑制することができるのである。[Function] By adopting the above-mentioned constitution method, the active ingredient of Funori directly enters the body without any special impurities or chemical additives and is absorbed and acts on the lymphoid cells in a short time. It is possible to suppress the viral infection including HIV and its progress.
【０００８】[0008]
【実施例】次に、本発明の実施例を説明する。まず、市
販されている乾燥物とされたフノリを入手し、一回半枚
を１日に３回、沸かして飲用物とし、それを摂取した。
それを１週間実行することで破傷風、膠原病をはじめと
するリンパ系疾病の回復を得られた。Next, embodiments of the present invention will be described. First, commercially available dried funori was obtained, and one and a half pieces were boiled 3 times a day to make a drink, which was ingested.
By carrying it out for one week, recovery of lymphatic diseases such as tetanus and collagen disease was obtained.
【０００９】同様に乾燥物とされたフノリを熱湯で溶
き、例えば葛湯状の保形液状とし、それを飲用、あるい
は食用としても同等の効果が得られた。Similarly, dried dried funori was dissolved in hot water to form a shape-retaining liquid, for example, kudzu hot water, and the same effect was obtained when it was drunk or edible.
【００１０】さらに、このフノリを現在知られている坑
ＨＩＶの治療薬である核酸誘導体等の他の物質と坑ＨＩ
Ｖ活性測定試験を比較してみても、優るとも劣らない結
果が得られている。この試験方法は９６穴マイクロタイ
タープレートに、種々の濃度の試験物質と共にＨＩＶ感
染ＭＴー４細胞（２．５×１０4／ｗｅｌｌ，ＭＯＩ：
０．０１）を感染直後に加える。また、試験物質のＭＴ
ー４細胞に対する細胞毒性を知るため、同様に非感染細
胞を試験物質と共に培養する。ＣＯ2インキュベーター
で３７℃５日間培養した後、ＭＴＴ法で生存細胞数を測
定する。この結果、毒性もないことが有効性と共に判明
した。Further, this funori is combined with other substances such as nucleic acid derivatives, which are currently known anti-HIV therapeutic agents, in anti-HI.
Even when the V activity measurement tests are compared, results are obtained which are neither superior nor inferior. In this test method, HIV-infected MT-4 cells (2.5 × 10 4 / well, MOI: 96-well microtiter plate together with various concentrations of the test substance were used.
0.01) is added immediately after infection. Also, MT of the test substance
In order to know the cytotoxicity against -4 cells, uninfected cells are likewise incubated with the test substance. After culturing at 37 ° C. for 5 days in a CO 2 incubator, the number of viable cells is measured by the MTT method. As a result, it was proved that there is no toxicity together with the efficacy.
【００１１】上記の測定試験ではそのままのフノリと、
ミクロフィルターで菌糸を濾過したフノリの二種につい
て実行されたがいずれもその内容は同等であり、フノリ
の成分に坑ウイルス性があることが判明している。つま
り、その多糖類、蛋白多糖類が有効性を有するものであ
り、それがＨＩＶをはじめとするウイルスのリンパ系細
胞への付着阻害、ならびにＨＩＶの増殖過程の必須酵素
である逆転写酵素（ＲＴａｓｅ）の阻害活性があるので
ある。In the above measurement test, as it is,
It was carried out for two types of funori whose hyphae were filtered with a microfilter, but the content was the same in both, and it was found that the components of funori are antiviral. In other words, the polysaccharides and protein polysaccharides are effective, and they inhibit the adhesion of viruses such as HIV to lymphoid cells and reverse transcriptase (RTase) which is an essential enzyme in the proliferation process of HIV. ) Has an inhibitory activity.
【００１２】[0012]
【発明の効果】本発明に係るフノリの使用方法は上記の
ように構成されている。そのため、フノリの含有する有
効成分が不純物なく、体内へ吸収され、リンパ系疾病、
例えばエイズをはじめ、破傷風、膠原病等に作用し、ま
た、その副作用もない。さらには、フノリをパップ剤と
して患部（腫れたリンパ腺部）へ貼付すればより一層の
効果も望めることとなる。The method of using funori according to the present invention is constructed as described above. Therefore, the active ingredients contained in Funori are absorbed into the body without impurities, lymphatic diseases,
For example, it acts on AIDS, tetanus, collagen disease, etc., and has no side effects. Further, if Funori is applied as a poultice to the affected area (swollen lymph gland area), a further effect can be expected.
Claims (2)
とすることを特徴とするフノリの使用方法。1. A method of using Funori, which comprises melting Funori to form a liquid liquid and making it a drink.
もしくは食用物とすることを特徴とするフノリの使用方
法。2. A method for using Funori, which comprises melting the Funori to obtain a shape-retaining liquid to prepare a drink or an edible material.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP5050210A JPH0825895B2 (en) | 1993-02-16 | 1993-02-16 | How to use Funori |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP5050210A JPH0825895B2 (en) | 1993-02-16 | 1993-02-16 | How to use Funori |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH06239760A JPH06239760A (en) | 1994-08-30 |
| JPH0825895B2 true JPH0825895B2 (en) | 1996-03-13 |
Family
ID=12852740
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP5050210A Expired - Lifetime JPH0825895B2 (en) | 1993-02-16 | 1993-02-16 | How to use Funori |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH0825895B2 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20020048835A (en) * | 2000-12-18 | 2002-06-24 | 주종재 | Use of water extract of Gloiopeltis furcata as an inhibitor for the action of TCDD (2,3,7,8-Tetrachlorodibenzo-p-dioxin). |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6047667A (en) * | 1983-08-25 | 1985-03-15 | Takaaki Mito | Funori (glue plant) health food and production thereof |
| JPS6047666A (en) * | 1983-08-25 | 1985-03-15 | Takaaki Mito | Funori (glue plant) health food and production thereof |
| JPH0825893B2 (en) * | 1987-06-18 | 1996-03-13 | 呉羽化学工業株式会社 | Antiviral agent |
| JPH0742234B2 (en) * | 1989-02-10 | 1995-05-10 | 株式会社紀文食品 | Reverse transcriptase inhibitor |
-
1993
- 1993-02-16 JP JP5050210A patent/JPH0825895B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JPH06239760A (en) | 1994-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Nakashima et al. | Inhibition of replication and cytopathic effect of human T cell lymphotropic virus type III/lymphadenopathy-associated virus by 3'-azido-3'-deoxythymidine in vitro | |
| Lemaitre et al. | Protective activity of tetracycline analogs against the cytopathic effect of the human immunodeficiency viruses in CEM cells | |
| Nakashima et al. | Purification and characterization of an avian myeloblastosis and human immunodeficiency virus reverse transcriptase inhibitor, sulfated polysaccharides extracted from sea algae | |
| Ito et al. | Inhibitory effect of glycyrrhizin on the in vitro infectivity and cytopathic activity of the human immunodeficiency virus [HIV (HTLV-III/LAV)] | |
| US5585365A (en) | Antiviral polysaccharide | |
| JPH03503635A (en) | Coumarins inhibit reverse transcriptase in humans | |
| CA2268709A1 (en) | Hiv protease inhibitors | |
| US20130131158A1 (en) | Antiviral composition | |
| MXPA01000195A (en) | Compounds obtained from salvia. | |
| CN115745830A (en) | Binaphthyl dicarboxylic acid derivative, and preparation method and application thereof | |
| US12295967B2 (en) | Pharmaceutical composition for prevention or treatment of flavivirus infection | |
| INOUYE et al. | Screening for inhibitors of avian myeloblastosis virus reverse transcriptase and effect on the replication of AIDS-virus | |
| JP3017630B2 (en) | HIV-type virus activity inhibitor | |
| JPH0825895B2 (en) | How to use Funori | |
| Chang et al. | Dextran sulfate as an inhibitor against the human immunodeficiency virus | |
| JPH10506124A (en) | COMPOSITION HAVING ANTIVIRUS PROPERTIES AND PROCESS FOR PRODUCING THE SAME | |
| JPH02157297A (en) | Dietary agent containing alpha-amylase inhibitor obtained from wheat | |
| JP2020532588A (en) | Cyanobacterial extract, its preparation and usage | |
| WO2016156920A1 (en) | Producing herbal medicine with mosquito stomach enzyme to treat virus and aids | |
| EP0198878B1 (en) | Application of diethyldithiocarbamate (dtc) to the preparation of a drug and preparation process thereof | |
| JP4121957B2 (en) | Indigo preparation and its use in preventing or treating human immunodeficiency virus infection | |
| TANAKA et al. | Inhibition by sakyomicin A of avian myeloblastosis virus reverse transcriptase and proliferation of AIDS-associated virus (HTLV-III/LAV) | |
| CN114668763A (en) | Application of etravirine in the preparation of drugs against tick-borne encephalitis virus, West Nile virus, yellow fever virus and chikungunya virus infection | |
| DE68919301T2 (en) | Use of a prolyl endopeptidase inhibitor for the treatment of AIDS. | |
| JPH0466536A (en) | Antiviral substance and production thereof |